Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference
Metacrine, Inc. (Nasdaq: MTCR) is set to present at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, at 4:20 p.m. ET. CEO Preston Klassen will lead the discussion, which will be broadcast live on the company's investor website. Metacrine focuses on developing therapies for liver and gastrointestinal diseases, utilizing a proprietary farnesoid X receptor platform. Its product candidates, MET409 and MET642, are in clinical trials for non-alcoholic steatohepatitis (NASH), with MET409 also targeting type 2 diabetes.
- None.
- None.
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine, will present at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 4:20 p.m. ET.
The live webcast will be available in the investor section of the company's website at www.metacrine.com. The webcast will be archived for 60 days following the presentation.
About Metacrine
Metacrine, Inc. (Nasdaq: MTCR) is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated a differentiated and improved therapeutic profile in clinical trials. The company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH). MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being advanced into a 16-week monotherapy trial in patients with NASH.
Contact:
Chelcie Lister
THRUST Strategic Communications
910.777.3049
investors@metacrine.com
FAQ
When is Metacrine's presentation at the SVB Leerink Healthcare Conference?
Who is presenting for Metacrine at the conference?
Where can I watch Metacrine's presentation?
What are Metacrine's product candidates for NASH?
What is the focus of Metacrine's research?
